Large telehealth players have shifted from being a threat (via compounded drugs) to being a primary sales channel for branded pharmaceuticals. For new launches like Oral Wegovi, telehealth is now a major driver of prescriptions, demonstrating a crucial evolution where these platforms have become friends, not foes, to pharma companies.

The direct-to-consumer channel exploded for Eli Lilly with Zepbound. The drug was a perfect fit because the diagnosis is simple, efficacy is easily measured by the patient, and it allows motivated self-pay customers to bypass insurance friction.

For out-of-pocket drugs like oral Wegovy, Novo Nordisk leverages telehealth platforms for distribution. This GTM strategy achieves rapid patient uptake, contrasting with slower, traditional models that rely on educating and detailing primary care physicians, reaching 300,000 UK patients in weeks.

The massive success of GLP-1s is not just about a $100B drug class. It's the first commercial proof that consumers are actively choosing preventative medicine, paving the way for a broader, trillion-dollar revolution in public health spending and behavior.

The emergence of low-cost, compounded versions of GLP-1 drugs from telehealth companies like Hims is creating significant pricing pressure on market leaders Novo Nordisk and Eli Lilly. This dynamic has pushed the pharma giants toward direct-to-consumer models with lower prices to compete.

The key catalyst for GLP-1 weight-loss drugs becoming mainstream wasn't just effectiveness, but a drastic price drop. Moving from over $1,000/month to as low as $25/month with insurance transformed the drug from a luxury good into an accessible, subscription-like product, paving the way for mass adoption.

Eli Lilly's oral GLP-1 is proving to be a market expander, not just a cannibalizer of injectables. An overwhelming 80% of its users are new to the GLP-1 class, driven by an aggressive direct-to-consumer (DTC) telehealth strategy. This signals a vast, untapped patient population for oral obesity treatments.

Eli Lilly's direct-to-consumer model for GLP-1s has been a massive success, with over half of new users coming through this channel. It shows consumers crave a streamlined, digital experience and want to bypass traditional healthcare system frictions.

The rapid success of the two-person startup MedV in the competitive telehealth space demonstrates a key market dynamic. When consumer demand is overwhelming, as with GLP-1 drugs, it creates openings for new, nimble companies to scale rapidly, even against established players with significant resources.